• Alteon Inc., of Ramsey, N.J., received $646,500 from the sale of its net operating loss carryovers under the State of New Jersey's technology business tax certificate transfer program. During the program's four-year existence, Alteon has received about $6 million in non-equity cash. Earlier this week Alteon closed an agreement to sell common stock to a group of institutional investors, raising proceeds of $3 million.

• Nymox Pharmaceutical Corp., of Maywood, N.J., reported a private placement of $712,500. Shares were priced between $3.75 and $4.10, for a total of 178,500 common shares with no warrants. Nymox, which two months ago received FDA clearance for its NicAlert smoking and tobacco product exposure test, said it would direct the funds toward general corporate purposes.

• Orchid BioSciences Inc., of Princeton, N.J., obtained a $10 million credit facility from Comerica Inc., of Detroit. Orchid said it would use the credit, which is composed of a $10 million revolving line of credit based on accounts receivable, for working capital in a push to achieve profitability next year.

• PerkinElmer Inc., of Boston, said it substantially completed a previously announced refinancing plan to repay existing debt in order to extend existing shorter-term debt maturities. The company said it repaid its existing bank debt and synthetic lease through the sale of $300 million aggregate principal amount of 10-year senior subordinated notes and entering into new senior secured credit facilities for a $315 million six-year term loan and a $100 million revolving credit facility. PerkinElmer also was paid about $110.3 million aggregate principal amount of its outstanding 6.80 percent notes due Oct. 15, 2005, pursuant to its cash tender offer and consent solicitation. PerkinElmer said its pending cash tender offer to purchase its zero-coupon convertible debentures due Aug. 7, 2020, was scheduled to expire at midnight Friday.